NCT01784913 2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2 Completed
Clinical Trials
12 trialsNCT00064129 2020-07-30
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed
NCT00113984 2019-12-16
Vaccine and Antibody Treatment of Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00309894 2019-08-05
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
University of California, San Francisco
Phase 2 Completed
NCT00274287 2019-03-28
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Oncology Specialists, S.C.
Phase 2 Completed
NCT00448409 2016-03-17
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00305669 2014-06-25
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT00908141 2013-08-23
GM-CSF in Treating Patients With Relapsed Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00045227 2013-06-19
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004029 2013-02-11
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed